| Literature DB >> 30002821 |
Danielle Vuichard Gysin1,2, Barry Cookson3, Henri Saenz4, Markus Dettenkofer5, Andreas F Widmer1.
Abstract
Background: Definitions and practices regarding use of contact precautions and isolation to prevent the spread of gram-positive and gram-negative multidrug-resistant organisms (MDRO) are not uniform.Entities:
Keywords: Barriers; Contact precaution; Implementation; Isolation; Multi-drug resistant organisms
Mesh:
Year: 2018 PMID: 30002821 PMCID: PMC6038251 DOI: 10.1186/s13756-018-0366-5
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Core elements of contact precautions (CP) recommended by recent ESCMID and HICPAC/CDC guidelines
| ESCMID 2014 (3) | HICPAC/CDC 2007 (2) | |
|---|---|---|
| Indication for CP | Colonization or infection with MDRO | Colonization or infection with MDRO |
| Donning and wearing of gloves and gowns | Gown and gloves are donned upon entry to a room | Gown and gloves are donned upon room entry |
| Disposal of gowns and gloves | Not stated | Gown and gloves are discarded before exiting the patient room |
| Additional requirements & recommendations | Use of disposable single-use or patient-dedicated non-critical care equipment (e.g. blood pressure cuffs and stethoscopes). | Use of patient-dedicated or single-use disposable noncritical equipment |
| Placement of patients | Special isolation wards | Single patient room preferred |
CDC centers for disease control and prevention, CP contact precaution, ESCMID european society of clinical microbiology and infectious diseases, HICPAC healthcare infection control practices advisory committee, MDRO multidrug resistant organism
Indication and specification for contact precautions (CP) and isolationa
| MRSA | GRE | | Non- | |||||||||
| EU | Non EU | EU | Non EU | EU | Non EU | EU | Non EU | |||||
| No CP | 12.7 | 24.5 | 0.165 | 30.0 | 32.7 | 0.396 | 32.7 | 34.7 | 0.636 | 23.3 | 34.7 |
|
| CP only if infected | 16.7 | 10.2 | 54.7 | 44.9 | 14.7 | 10.2 | 17.3 | 6.1 | ||||
| CP if colonised and/or infected | 68.0 | 65.3 | 15.3 | 22.4 | 44.7 | 40.8 | 50.7 | 40.8 | ||||
| Unknown | 42.7 | 0 | 0 | 0 | 5.3 | 10.2 | 6.0 | 14.3 | ||||
| ESBL not determined | n.a. | n.a. | n.a. | n.a. | 2.7 | 4.1 | 2.7 | 33.3 | ||||
| Total no. responses (%) | 150 (75.4) | 49 (24.6) | 131 (74.9) | 44 (24.1) | 150 (75.4) | 47 (24.6) | 150 (75.4) | 49 (24.6) | ||||
| Gowns and gloves whenever entering the room | 57.3 | 62.9 | 0.398 | 59.0 | 56.7 | 0.623 | 44.9 | 59.1 | 0.234 | 47.3 | 71.4 |
|
| Gowns and gloves if direct contact is anticipated | 37.9 | 37.1 | 37.1 | 43.3 | 55.1 | 40.9 | 52.7 | 28.6 | ||||
| Other procedures (e.g. standard precautions only) | 4.8 | 0.0 | 3.8 | 0.0 | 0 | 0 | 0 | 0 | ||||
| Total no. responses (%) | 124 (78.0) | 35 (22.0) | 105 (77.8) | 30 (22.2) | 89 (80.2) | 22 (19.8) | 93 (81.6) | 21 (18.4) | ||||
| Single room | 62.5 | 63.8 | 59.4 | 56.3 | 0.703 | 31.4 | 31.3 | 0.960 | 36.4 | 27.1 | 0.494 | |
| Cohorting | 17.4 | 10.6 | 16.1 | 16.7 | 19.3 | 18. | 20.7 | 18.8 | ||||
| Spatial separationc | 10.4 | 6.4 | 0.235 | 9.8 | 6.3 | 13.6 | 16.7 | 13.6 | 20.8 | |||
| No specific measures | 9.7 | 19.1 | 14.7 | 20.8 | 35.7 | 33.3 | 29.3 | 33.3 | ||||
| Total no. responses (%) | 144 (75.4) | 47 (24.6) | 143 (74.9) | 48 (25.1) | 140 (74.5) | 48 (25.5) | 140 (74.5) | 48 (25.5) | ||||
| Carbapenem resistant | Carbapenem resistant non- | MDR | MDR | |||||||||
| EU | Non EU | EU | Non EU | EU | Non EU | EU | Non EU | |||||
| No CP | 11.3 | 16.3 | 0.745 | 8.2 | 18.4 | 0.246 | 13.3 | 20.4 | 0.597 | 9.3 | 20.4 | 0.171 |
| CP only if infected | 14.0 | 10.2 | 13.6 | 10.2 | 17.3 | 14.3 | 17.3 | 20.4 | ||||
| CP if colonised and/or infected | 65.3 | 63.3 | 72.1 | 65.3 | 60.0 | 59.2 | 62.7 | 51.0 | ||||
| Unknown | 9.3 | 10.2 | 6.1 | 6.1 | 9.3 | 6.1 | 10.7 | 8.2) | ||||
| Total no. responses (%) | 150 (75.4) | 49 (24.6) | 147 (75.0) | 49 (25.0) | 150 (75.4) | 49 (24.6) | 150 (75.4) | 49 (24.6) | ||||
| Gowns and gloves whenever entering the room | 61.3 | 68.8 | 0.440 | 63.5 | 60.6 | 0.763 | 56.3 | 64.7 | 0.389 | 58.7 | 61.3 | 0.797 |
| Gowns and gloves if direct contact is anticipated | 38.7 | 31.3 | 36.5 | 39.4 | 43.7 | 35.3 | 41.3 | 38.7 | ||||
| Total no. responses (%) | 111 (77.6) | 32 (22.4) | 115 (77.7) | 33 (22.3) | 103 (75.2) | 34 (24.8) | 109 (77.9) | 31 (22.1) | ||||
| Single room | 64.1 | 41.7 |
| 71.6 | 47.9 |
| 56.7 | 43.8 | 0.156 | 61.6 | 45.8 | 0.067 |
| Cohorting | 13.4) | 14.6 | 12.1 | 18.8 | 18.7 | 14.6 | 18.1 | 14.6 | ||||
| Spatial separationc | 9.9 | 20.8 | 7.1 | 14.6 | 12.7 | 18.8 | 8.7 | 18.8 | ||||
| No specific measures | 12.7 | 22.9 | 9.2 | 18.8 | 11.9 | 22.9 | 11.6 | 20.8 | ||||
| Total no. responses (%) | 142 (74.7) | 48 (25.3) | 141 (74.6) | 48 (25.4) | 134 (73.6) | 48 (26.4) | 138 (74.2) | 48 (25.8) | ||||
aValues are percentages (related to the corresponding total respondents) unless indicated otherwise
bA two-sided p-value of < 0.05 was considered statistically significant
cShared room with MDRO-negative patients but with optical barrier (e.g. red margin on the floor) or separated by screen/curtains
Other specific requirements and conditions for contact precaution (CP)
| MDRO | Origin of responses | Total responses | Additional pre-emptive CP based on patient’s historya | CP only required if specific risk factors presentb | Additional pre-emptive CP but only if specific risk factors | None applicable | |
|---|---|---|---|---|---|---|---|
| MRSA | EU | 126 | 117 (92.9) | 1 (0.8) | 1 (0.8) | 7 (5.6) |
|
| Non EU | 38 | 30 (78.9) | 1 (2.6) | 2 (5.3) | 5 (13.2) | ||
| GRE | EU | 94 | 81 (86.2) | 3 (3.2) | 1 (1.1) | 9 (9.6) | 0.265 |
| Non EU | 30 | 24 (80.00) | 2 (6.7) | 2 (6.7) | 2 (6.7) | ||
| ESBL | EU | 91 | 74 (81.3) | 8 (8.8) | 4 (4.7) | 5 (4.7) | 0.812 |
| Non EU | 26 | 22 (84.6) | 1 (3.8) | 2 (7.7) | 1 (3.8) | ||
| ESBL non- | EU | 101 | 86 (85.1) | 5 (5.0) | 3 (3.0) | 7 (6.9) | 0.131 |
| Non EU | 23 | 18 (78.3) | 3 (13.0) | 2 (8.7) | 0 (0.0) | ||
| Carbapenem resistant | EU | 120 | 103 (85.8) | 4 (3.3) | 4 (3.3) | 9 (7.5) | 0.465 |
| Non EU | 36 | 33 (91.7) | 0 (0.0) | 2 (5.6) | 1 (2.8) | ||
| Carbapenem resistant Enterobacteriaceae (non- | EU | 126 | 111 (88.1) | 2 (1.6) | 4 (3.2) | 9 (7.1) | 0.560 |
| Non EU | 37 | 33 (89.2) | 1 (2.7) | 2 (5.4) | 1 (2.7) | ||
| MDR | EU | 112 | 96 (85.7) | 3 (2.7) | 4 (3.6) | 9 (8.0) | 0.178 |
| Non EU | 35 | 31 (88.6) | 1 (2.9) | 3 (8.6) | 0 (0.0) | ||
| MDR A. baumannii | EU | 120 | 107 (89.2) | 1 (0.8) | 5 (4.2) | 7 (5.8) | 0.758 |
| Non EU | 33 | 31 (91.2) | 0 (0.0) | 2 (5.9) | 1 (2.9) |
aFormerly positive for respective MDRO or presumptive infection/colonization with respective MDRO
bCP only when certain risk factors present e.g. incontinence, diarrhoea, draining wounds
cA two-sided p-value of < 0.05 was considered statistically significant
Fig. 1Most commonly encountered barriers when trying to implement contact precaution and isolation measures from the survey respondents’ perspective (n = 194, 4 missing from non-EU and 15 missing from EU countries)